pharmaphorum2d
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...
NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).
ET HealthWorld2d
Roche secures Zealand obesity drug candidate for up to $5.3 billion
The agreement covering the compound petrelintide, announced by Roche on Wednesday, marks renewed efforts to catch up with weight-loss market leaders Novo Nordisk and Eli Lilly .
Viking Therapeutics closer to bringing its Ozempic competitor to market
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...